Stocks declined last week, posting a second straight weekly loss following a hawkish Fed meeting and mixed inflation data. The Federal Reserve lifted its benchmark interest rate for the seventh and final time this year, approving a 50 basis point increase. Market participants were relieved to see a ramp down from the previous 75 basis point hikes but were discouraged by the Fed’s forward outlook, which calls for a higher benchmark target range for 2023 than initially outlined. The major indices retreated following Wednesday’s announcement, then were further dragged down on Thursday by retail sales figures for November that came in well below expectations. For the week, the Dow shed 1.7%, the S&P 500 fell 2.1%, and the Nasdaq contracted 2.7%. 

With only two weeks left in 2022, recession fears continue to weigh heavily on markets. In the coming week, traders will be tuned in for the November update to the Personal Consumption Expenditures Price Index (PCE), the Fed’s preferred gauge for tracking inflation. Market participants are hoping for a signal that inflation continued to moderate last month and that the Fed will be able to tamp inflation without pushing the economy into a recession. The housing market will also be in focus, with the NAHB Housing Market Index due for release on Monday, followed by data on new and existing home sales for November.  

One of the hardest hit sectors of the year, real estate, has been a bright spot in markets recently, thanks to fast-falling mortgage rates. According to bankrate.com, the national average for a 30-year fixed mortgage hit a high of 7.2% on November 11th and has since pulled back to around 6.5%. Homebuilders have benefited from the deep dive over the past few weeks and should continue to do so as long as mortgage rates continue to lower. 

According to some Wall Street pros, we may have a “once-in-a-cycle opportunity” to cash in on the early-cycle outperformance phase of homebuilder stocks, begging the question – which home builders are best positioned in the lower-mortgage-rate environment?    

Companies likely to be best positioned are the largest-scale players. Our first recommendation for the week ahead is the number one home builder in America since 2002, D. R. Horton Inc (DHI).   Founded in 1978 in Fort Worth, Texas, D.R. Horton operates in 106 markets in 33 states across the United States and closed 83,518 homes in its homebuilding and single-family rental operations during its fiscal year ended September 30th, 2022. 

The company is engaged in constructing and selling high-quality homes through its diverse brand portfolio, which includes Emerald Homes, Express Homes, and Freedom Homes, with sales generally ranging from $200,000 to over $1,000,000. It also provides mortgage financing, title services, and insurance agency services for its homebuyers through its mortgage, title, and insurance subsidiaries. 

In its most recent quarter, D.R. Horton missed analyst estimates for earnings and revenue due to the cooling housing market. From June to September 2022, the company’s total homebuilding lot position decreased by 25,000 lots, but the company has been actively managing the lot and land pipeline and investments in lots, land, and development to meet needs during this transition in the housing market. 

Impressive performance, industry-leading market share, a solid acquisition strategy, a well-stocked land supply, lots, and homes, along with affordable product offerings across multiple brands, are expected to drive growth. D.R. Horton’s earnings are expected to grow 1.7% in fiscal 2023. The stock has gained 24.9% over the past three months, outperforming the industry’s 19% rise. DHI stock has a solid Buy rating from the pros offering recommendations. A median price target of $95 represents an increase of 8% from Friday’s closing price. 

The airline industry has seen a remarkable recovery in 2022 thanks to increasing travel demand and consumers’ willingness to pay higher fares. With airline stocks currently trading at very low multiples, many long-term-minded investors are eyeing the group, wondering which of these beaten-down tickers is the most attractive value.

Delta Airlines (DAL), the second airline company to have joined the coveted S&P 500 Index, commands more than a 17% share of the domestic aviation market. As you would expect, most of the Atlanta-GA-based carrier’s revenues are realized from its airline segment. What might surprise you is that 10% of the $29.9-billion amount generated in 2021 came from the company’s refinery segment, which operates for the benefit of the airline division by providing it with jet fuel from its own production.

Fuel savings are crucial to a functioning aviation industry in this next chapter. From increasing costs to environmental impact, airlines have had plenty of reasons to save every bit of jet fuel they can. Delta recently revealed details of how its fleet renewal program has helped to save tens of millions of gallons of fuel.  

Last week, the airline heavyweight raised its Q4 and full-year 2022 guidance and forecast an upbeat 2023, driven by robust demand. The company now expects the fourth-quarter 2022 operating margin to be 11%. Management sees adjusted earnings per share in the $1.35-$1.40 range (the earlier outlook was $1-$1.25). For the full-year 2023, DAL expects 15-20% year-over-year revenue growth. Earnings per share and operating margin for 2023 are expected in the $5-$6 band and 10-12% range, respectively. 

Delta has been more conservative than some competitors in bringing back capacity, but the carrier aims to have its network restored to 2019 levels next summer. In the meantime, several competitors have had to cut routes and scale back on expansion plans as supply chain, and labor constraints have delayed the production of new aircraft. Airlines continue to struggle with labor shortages, but for Delta, bookings remain strong into early 2023.

Delta shares are currently very cheaply priced at less than eight times earnings. The stock garners an 85% Buy rating on Wall Street. A median consensus price target of $45 represents a 36% increase from the last price.  

As long as marijuana remains illegal at the federal level, access to credit markets for pot companies will be spotty at best. Marijauana-focused real estate investment trust Innovative Industrial Properties (IIPR) buys medical marijuana cultivation and processing facilities in legalized states with cash and leases these properties back to the seller. It’s a win-win agreement that provides money to cannabis companies while netting IIP long-term tenants.

IIPR provides investors ground floor access to exponential growth potential along with the reliability of a REIT. As of early November, Innovative Industrial Properties owned 111 properties covering 8.7 million square feet of space in 19 states. Over the past five years, IIPR’s quarterly dividend payout has grown by 1,100%. The REIT currently boasts a 7.74% yield.  

After two positive weeks in a row, the major U.S. stock indexes fell last week on mixed economic data as recession concerns intensified. Investors are worried that recent mixed inflation data could challenge the Federal Reserve’s expectations of slowing the pace of interest-rate increases. For the week, the Dow shed 2.8%, the S&P 500 fell 3.4%, and the Nasdaq lost 4%. 

In the coming days, investors will be focused on the latest inflation data due for release and the two-day Fed policy meeting, with central bankers expected to announce an interest rate decision and near-term projections for the U.S. economy on Wednesday. Fed policymakers are widely expected to hike interest rates by an additional 50 basis points in their ongoing effort to tamp high inflation. This will be the seventh and final rate hike for 2022. The Fed has raised its benchmark rate by a cumulative 375 basis points so far this year, in the fastest tightening cycle in over 40 years.

Since the U.S. government officially introduced the first-ever tax credit for clean energy storage projects, there have been remarkable positive business developments in the industry. At the end of 2021, the global installed energy storage capacity measured about 46 GWh.  According to InvestorPlace, a meager 1.5% of renewable energy production in the world is backed by energy storage today. As governments and corporations worldwide strive toward carbon neutrality, that figure is set to grow exponentially. This week’s first recommendation is a pure play on advanced energy storage with enormous upside potential.  

Stem Inc (STEM) is a pure play on the smart energy storage space offering artificial intelligence-driven clean energy storage systems. The company’s advanced energy storage solutions with Athena(TM), an artificial intelligence-powered analytics platform, enables customers and partners to optimize energy use by automatically switching between battery power, onsite generation, and grid power.

The company has already built up considerable infrastructure with established names. STEM’s Athena Software seems likely to become mission-critical for many electric utilities because of the rapidly increasing supply and demand for renewable energy.  

For the third quarter, Stem reported a record-breaking backlog of $727 million, up 191% from $250 million at the end of Q2 2021. Bookings were up 402% from $45 million to $226 million, and the 12-month pipeline increased 8% from the previous quarter to $5.2 billion. Revenue grew a whopping 246% year-over-year and came in 5% above the high end of guidance at $67 million. 

We are encouraged by Congressional support for the Inflation Reduction Act of 2022. The climate provisions in the Act would drive continued investment in America’s aging power grid, support customer adoption of renewable energy, and improve energy security by incentivizing development of our domestic supply chain. Importantly, a stand-alone Investment Tax Credit (ITC) for energy storage, and the extension of the solar ITC, would improve the economic returns for our customers.”  

“Supply chain constraints, permitting and interconnection delays, and certain regulatory actions continue to pose challenges, but we believe we remain well-positioned to manage these risks and continue with our strong execution through the rest of 2022,” commented John Carrington, Chief Executive Officer of Stem.

STEM has high growth potential and looks like an ideal long-term investment. The company’s Athena platform seems like an industry changer with wide-ranging applications. STEM’s infrastructure is far ahead of its competitors and will likely prove to be a crucial piece of the investment thesis moving forward. Of the 11 analysts covering the stock, 9 rate it a Buy, and 2 rate it a Hold. There are no sell ratings for STEM. A median price target of $19.50 represents an increase of 85% from Friday’s closing price.  

37 U.S. states and four U.S. territories have laws that permit the use of marijuana. While it is still  illegal on a Federal level, President Biden’s recent proclamation included a request for the attorney general “to initiate the administrative process to review expeditiously how marijuana is scheduled under federal law.”  Many see this as a significant step in the right direction, but it’s expected to be a slow road.    

Potential legalization of cannabis is likely to be a major positive catalyst for the leader in net cannabis revenue, Tilray (TLRY). The company has a presence in all key markets, with a focus on recreational and medicinal cannabis; the addressable market is significant and expanding. 

TLRY surged following the recent announcement that President Biden would encourage the reassessment of marijuana laws but gave back some of those gains when the company reported Q1 2023 revenue and EPS misses. The company has its sights set on Revenue of $4 billion by 2024, a realistic target if regulatory hurdles wane. At $3.48 per share, TLRY currently trades at -6.5x forward earnings.   The stock remains deeply oversold and is worth buying even after the recent uptick.

Global healthcare leader Eli Lilly And Company (LLY) has been creating high-quality medicines for over a century. The drug firm focuses on endocrinology, oncology, neuroscience, and immunology. Key products include Trulicity, Jardiance, and Humulin for diabetes; Taltz and Olumiant for immunology; and Verzenio and Alimta for cancer.  

The mega-cap pharmaceutical giant’s pipeline is locked and loaded with promising advancements, which means plenty of potential upcoming opportunities for investors to benefit from. In the first half of 2022, Lilly received word that the FDA was fast-tracking its investigation of tirzepatide. A drug designed to treat adults who are overweight with weight-related comorbidities such as diabetes. Eli Lilly expects its rolling application to be completed by April 2023.

JPMorgan analyst Chris Schott recently summed up his bullish outlook on LLY. The analyst believes that Eli Lilly remains the best-positioned growth story in his coverage and one of his top picks following the stock’s pullback over the past month. The analyst sees a “significant opportunity” for Tirzepadite in type 2 diabetes, and obesity, which in his view “warrants increased attention.”  Schott currently gives the stock an Overweight rating and a $300 price target.  

Lilly’s share price is up nearly 33% in 2022 and seems likely to continue to gain steam into the new year. The stock sports a dividend of $0.98 or 1.21% annually. LLY’s dividend payout for the year is set for the low 40% range, which should allow for robust future dividend growth.

A strong pipeline and a stable dividend make Eli Lilly an attractive consideration. The pros on Wall Street also think so. Among 17 polled analysts, 14 say to Buy LLY, 2 call it a Hold, and only one rates the stock a Sell. A median 12-month price target of $351 represents a 9% increase from its current price.